Anti-thrombin therapy

  • Anthony A Bavry
  • Deepak L Bhatt


This chapter reviews the anti-thrombin agents (also known as anti-coagulants), which include the heparins (unfractionated heparin and low-molecular heparin [i.e., enoxaparin]), direct thrombin inhibitors (i.e., bivalirudin), and factor Xa inhibitors (i.e., fondaparinux). The interest behind the use of anti-thrombin agents stems from the fact that ACS patients who are only treated with anti-platelet agents are still at risk of significant ischemic events. The clinical trial experience with these agents crosses several decades. This span includes an early era with relatively nonaggressive antiplatelet therapies (i.e., infrequent or no aspirin, thienopyridines, glycoprotein IIb/ IIIa inhibitors), or adjuvant therapies (i.e., statins). This earlier time period was also largely characterized by noninvasive therapy, which is not currently considered the standard of care for ACS patients. Accordingly, the substantial improvement in medical therapy and invasive management of patients with ACS makes interpretation of the early trial experience relatively difficult, compared with the newer cardiovascular agents. Our discussion will start with heparin, which is the oldest anti-thrombin agent in the care of ACS patients.


Percutaneous Coronary Intervention Acute Coronary Syndrome Major Bleeding Unfractionated Heparin Direct Thrombin Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000; 355:1936–1942.CrossRefGoogle Scholar
  2. 2.
    Lauer MA, Houghtaling PL, Peterson JG, et al. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes. Observations from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial. Circulation 2001; 104:2772–2777.CrossRefGoogle Scholar
  3. 3.
    Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126:188S–203S.CrossRefGoogle Scholar
  4. 4.
    Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction. Circulation 2007; 116:803–877.CrossRefGoogle Scholar
  5. 5.
    Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Circulation 2004; 110:e82–e293.CrossRefGoogle Scholar
  6. 6.
    Harjai KJ, Stone GW, Grines CL, et al. Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiveing glycoprotein IIb/IIIa inhibitors. Am J Cardiol 2007; 99:202–207.CrossRefGoogle Scholar
  7. 7.
    Antman, EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100:1602–1608.CrossRefGoogle Scholar
  8. 8.
    Ferguson JJ, Califf RM, Antman EM, et al.; SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy. Primary results of the SYNERGY randomized trial. JAMA 2004; 292:45–54.CrossRefGoogle Scholar
  9. 9.
    Petersen JL, Mahaffey, KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin for unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes. A systematic overview. JAMA 2004; 292:89–96.CrossRefGoogle Scholar
  10. 10.
    Yusuf S, Mehta SR, Xie C, et al.; CREATE Trial Group Investigators. Effects of reviparin, a low-molecularweight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005; 293:427–436.CrossRefGoogle Scholar
  11. 11.
    Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006; 354:1477–1488.CrossRefGoogle Scholar
  12. 12.
    Gibson CM, Murphy SA, Montalescot G, et al. Percutaneous coronary intervention in patients receiving _enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007; 49:2238–2246.CrossRefGoogle Scholar
  13. 13.
    Gurm HS, Bhatt DL. Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin _inhibitors. Am Heart J 2005; 149:S43–S53.CrossRefGoogle Scholar
  14. 14.
    Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355:2203–1226.CrossRefGoogle Scholar
  15. 15.
    HORIZONS AMI: Bivalirudin reduces bleeding, adverse clinical events in STEMI. Available at: www. Last accessed January 2008.Google Scholar
  16. 16.
    Rajagopal V, Bhatt DL. Factor Xa inhibitors in acute coronary syndromes: moving from mythology to reality. J Thromb Haemost 2005; 3:426–438.CrossRefGoogle Scholar
  17. 17.
    Cohen M, Bhatt DL, Alexander JH, et al. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor in percutaneous coronary intervention: the SEPIAPCI trial. Circulation 2007; 115:2642–2651.CrossRefGoogle Scholar
  18. 18.
    Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354:1464–1476.CrossRefGoogle Scholar
  19. 19.
    Yusuf S, Mehta SR, Chrolavicius S, et al.; OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction. JAMA 2006; 295:1519–1530.CrossRefGoogle Scholar

Copyright information

© Current Medicine Group, a part of Springer Science+Business Media 2008

Authors and Affiliations

  • Anthony A Bavry
    • 1
  • Deepak L Bhatt
    • 1
  1. 1.Department of Cardiovascular MedicineCleveland ClinicUSA

Personalised recommendations